Immune checkpoints, known as regulators of the immune system, are crucial to self-tolerance. The inhibitory checkpoint molecules function as brakes on the T cells, inhibiting immune activation, which contributes to tumor immune escape. James P. Allison and Tasuku Honjo individually studied two of the inhibitory checkpoint molecules, CTLA-4 and PD-1, showed their inhibitor antibodies' anti-tumor effect, provided new strategies for cancer therapy, and therefore won the 2018 Nobel Prize in Physiology or Medicine. In this paper, we introduce the laureates and their research experiences, interpret the mechanism of tumor and T-cell immunity, analyze the development status of checkpoint therapy, and finally predict the research direction of immune checkpoint.
ZHANG Na
,
ZHANG Linzheng
,
LIU Junxiang
. Release the brake on the immune system, constitute a landmark in the fight against cancer——Introduction of the 2018 Nobel Prize in Physiology or Medicine[J]. Science & Technology Review, 2019
, 37(21)
: 97
-104
.
DOI: 10.3981/j.issn.1000-7857.2019.21.009
[1] The Nobel Committee for Physiology or Medicine. Released the brakes of immunity[EB/OL]. (2018-10-01)[2019-01-22]. https//www.nobelprize.org/prizes/medicine/2018/press-release/.
[2] Smith-Garvin J E, Koretzky G A, Jordan M S. T cell activation[J]. Annual Review of Immunology, 2009, 27:591-619.
[3] James P A. Department of immunology, division of science[EB/OL].[2018-11-01]. https://faculty.mdanderson.org/profiles/james_allison.html.
[4] James P A. Immunotherapy immunotherapy stories scientists the University of Texas at MD Anderson Cancer Center[EB/OL].[2018-11-01]. https://www.cancerresearch.org/immunotherapy/stories/scientists/james-p-allison-phd.
[5] Leach D R, Krummel M F, Allison J P. Enhancement of antitumor immunity by CTLA-4 blockade[J]. Science, 1996, 271(5256):1734-1736.
[6] Krumel M F. CD28 and CTLA-4 have opposing effects on the response of T cell stimulation[J]. Journal of Experimental Medicine, 1995, 182:459-465.
[7] Tasuku Honjo[EB/OL].[2018-11-01]. https://kyouindb.iimc.kyoto-u.ac.jp/j/gA0zR.
[8] Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. The EMBO Journal, 1992, 11(11):3887-3895.
[9] Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor[J]. Immunity, 1999, 11(2):141-151.
[10] Freeman G J, Long A J, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. Journal of Experimental Medicine, 2000, 192(7):1027-1034.
[11] Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells[J]. International immunology, 2004, 17(2):133-144.
[12] Ghiotto M, Gauthier L, Serriari N. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1[J]. International Immunology, 2010, 22(8):651-660.
